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Abstract 
 
Purpose of review:  Artificial corneas are being developed to meet a shortage of donor corneas 
as well as to address cases where allografting is contraindicated. A range of artificial corneas has 
been developed. Here we review several newer designs and especially those inspired by naturally 
occurring biomaterials found with the human body and elsewhere. 
Recent findings: Recent trends in the development of artificial corneas indicate a move towards 
the use of materials derived from native sources including decellularized corneal tissue and 
tissue substitutes synthesized by corneal cells in vitro when grown either on their own, or in 
conjunction with novel protein-based scaffolds. Biologically inspired materials are also being 
considered for implantation on their own with the view to promoting endogenous corneal tissue. 
Summary: More recent attempts at making artificial corneas have taken a more nature-based or 
nature-inspired approach. Several will in the near future be likely to be available clinically. 
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Introduction 
 
According to the World Health Organisation, there are 285 million visually impaired individuals 
worldwide, of whom 39 million are blind [1]. Corneal blindness is the fourth largest cause of 
blindness, making up 5.1% of cases with an estimated 1.5 to 2.0 million new cases of unilateral 
blindness being reported annually [2]. While many of these patients can be treated by receiving a 
donor corneal tissue transplant, donor corneas are in limited supply globally and a high 
proportion of allografts, given sufficient time, will eventually fail due to immunological factors. 
In addition, there are instances where the use of donor tissue is contraindicated. For these reasons 
there has long been interest in developing alternatives to donor corneas as materials for restoring 
corneal tissue structure and function. 
 A number of prosthetic corneas or so-called keratoprostheses (KPros) are currently used 
clinically and improvements in design since first conception have led to acceptable performance. 
Examples include the Boston KPro [3], AlphaCor [4] and the osteo-odonto-keratoprosthesis or 
OOKP [5]. Significantly, two of these examples make use of natural materials to achieve a 
biocompatible host-graft interface. The Boston KPro uses a cross-linked human donor cornea 
rim as the interface [6], while the OOKP contains dental tissue wrapped with autologous oral 
mucosal cells. 
 More recently, the use of decellularized extracellular matrices (ECM) of various target 
organs have been proposed as scaffolds for regeneration. For example, a recent news article 
reports a clinical trial of 115 Chinese patients who were transplanted with decellularized porcine 
corneas [7]. The report states that “Seventy percent of the replaced corneas are clear”. These are 
technically xenografts and hence fall outside the scope of this review. As an alternative to solid 
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organ transplants (either human or animal) some groups have used corneal cells to construct their 
own ECM in vitro, while others have used ECM macromolecules and mimics to develop 
artificial corneas that induce endogenous cells from the host to migrate into the implant to affect 
the repair. There are various reviews on the different artificial corneas and their performance [8-
11]. Here, we review several of the artificial corneas that are inspired by nature and natural ECM 
materials, and discuss in detail the creation of tissue templates designed to promote corneal 
tissue regeneration following transplantation as opposed to solid organ transplants. 
 
The Original Artificial Corneas  
The term “artificial cornea” strictly speaking refers to keratoprostheses that comprise plastic 
polymers and other synthetic materials. However, more recently, this term has come to be used 
more broadly (albeit perhaps inappropriately) to refer to any material implanted with the view to 
to restoring the full structure and function of the cornea. Early KPros such as the Boston KPro, 
OOKP and AlphaCor have been helping individuals save their vision, when allografting was 
contraindicated. Newer iterations of KPros developed by Storsberg [12] and Myung [13] are 
using sophisticated surface coating and patterning techniques to obtain an optimal host-graft 
interface, and these are being tested clinically [12]. 
 
Artificial Corneas Fabricated from Biological Materials  
The ECM of any organ is composed of a range of both structural as well as instructional 
macromolecules. During embryonic development, primordial ECMs contribute to organogenesis 
by providing cues for the cells to convert the organ anlagen into a fully formed and functional 
organ [14]. In wound healing the same ECM macromolecules contribute to tissue repair and 
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regeneration, and therefore can be considered as ideal components for fabricating implants that 
would enable regeneration. Several newer “artificial corneas” that have been tissue engineered 
are therefore designed with the use of ECM components or polymers that mimic the ECM in its 
function.  
 
• Corneas from Self-Assembly  
One ingenious method for using ECM macromolecules is to coax the cells of the target organ to 
produce their own ECM. Germain and co-workers have developed a range of  “self assembled” 
human corneal equivalents. Their latest model uses all three corneal cell types [15]. They start by 
creating the stroma by culturing stromal fibroblasts in growth medium supplemented with 
ascorbic acid for 28–35 days. The ascorbic acid stimulates the fibroblasts to secrete extracellular 
matrix components such as collagen, forming sheets of 35-55 microns in thickness. These are 
then stacked together to form a corneal stroma. Corneal endothelial cells were then seeded on top 
of this stacked stroma and allowed to form a monolayer in endothelial growth medium. After two 
to seven days, a plastic ring is placed on top of the cultured construct and this is flipped upside 
down. Corneal limbal epithelial cells are then seeded on top and the entire construct is cultured 
in epithelial cell medium supplemented with more ascorbic acid. After another 7 days in culture 
to enable epithelial cell confluence, the entire construct is air-lifted and cultured at the air-liquid 
interphase to promote for stratification of the corneal epithelium. The resulting corneal construct 
as reported in Proulx et al. [15] was fairly transparent. However, it was only a fraction of the 
thickness of a human cornea. The authors suggest, however, that the required thickness can be 
readily achieved by simply increasing the number of stacked layers of fibroblast/ECM. There is 
no available information in the literature of clinical testing.  
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 More recently, Karamichos et al. [16] reported the use of ascorbic acid (with and without 
additional transforming growth factor-beta) to induce secretion of ECM by human umbilical cord 
mesenchymal stem cells (cord stem cells) to form a cornea stroma-like construct. In comparison 
to human cornea fibroblasts, the cord stem cells produced a more extensive matrix. In addition, 
the cells themselves differentiated into stroma-like cells. However, despite the ability of the 
umbilical cord stem cells to produce a stroma, it took four weeks to produce a construct that was 
24 mm in diameter and 30 microns thick.  
 A main drawback, therefore, is the long period of time required for the fabrication of a 
construct. The use of allogeneic cells might also be problematic, so implants fabricated in this 
manner will most likely be confined to autografts in patients in carefully pre-planned surgeries, 
as opposed to being an off-the-shelf solution. Nevertheless, self-assembled corneal stromal 
constructs could be decellularized and used as implants. This possibility has not been reported 
for the cornea but has been reported for tissue engineered cartilage [17]. 
 
• Collagen Based Constructs 
As collagen is the main structural component of the ECM, there has been a lot of interest in 
collagen-based implants. The main source of collagen is extracted animal protein, although 
marine collagen is now being used for tissue engineering [18]. Recent developments in the area 
include the use of plastically compressed collagen that was compressed with [19] and without 
pre-seeded keratocytes [20]. Compressed collagen as stromal substituted have now been tested in 
rabbits as implants. The implants were translucent, but non-immunogenic and supported 
epithelial overgrowth [19]. Vitrified collagen has also been used to fabricate membranes with 
good mechanical strength for corneal repair [21]. 
! (!
• Silk Fibroin Based Constructs 
While collagen is an obvious candidate for corneal reconstruction, materials of non-animal origin 
have also been explored, primarily in an effort to reduce production costs and limit potential 
exposure to infectious materials. One such material that has recently been explored in some 
detail, is the structural protein found within silkworm-derived silk fibers known as fibroin [22]. 
In particular, given its relatively safe history of prior clinical use (i.e. in the form of silk sutures), 
the majority of studies have been based upon fibroin produced by the domesticated silkworm 
Bombyx mori. 
 Aqueous solutions of peptide fragments derived from B. mori silk fibroin (BMSF) can be 
readily produced from whole cocoons using relatively simple and inexpensive processing 
techniques [23]. While little of the native full-length protein remains following processing, the 
resulting peptide solutions can subsequently be used to generate a variety of stable and 
biocompatible materials including freestanding membranes, electro-spun fibers and porous 
sponges [24]. Of these three materials, the freestanding BMSF membranes have received most 
attention for potential use in corneal tissue reconstruction owing to their high degree of 
transparency and general handling properties [25-28]. Importantly, subsequent studies have 
revealed that BMSF-based materials support the attachment, growth and differentiation of cells 
isolated from all three main tissue layers of the cornea [25, 28-30]. These results are in 
themselves quite remarkable given that BMSF, unlike collagen, does not possess specific 
structural motifs designed to promote cell attachment and growth. Nevertheless, a sufficient level 
of cell attachment can be achieved through use of serum-supplemented culture medium and the 
opportunity to customize cell attachment is supported through coating with either purified ECM 
components [30, 31] or peptides of choice [32]. Based upon these findings, one of our groups 
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(DGH) is currently engaged in preclinical studies of BMSF as a vehicle for delivering cells for 
corneal reconstruction. For example, BMSF membranes are being investigated for their potential 
to deliver limbal epithelial cell cultures to the ocular surface [28] and to implant corneal 
endothelial cells cultures to the posterior surface [30]. In addition, Lawrence et al. [26] have 
proposed using stacked layers of stromal cells grown on BMSF-membranes to repair the corneal 
stroma. Theoretically, combining these approaches could lead to creation of a full-thickness 
corneal tissue substitute as described in Figure 1. Preliminary studies by Higa et al. [27] indicate 
that single BMSF-membranes are well tolerated when implanted within the corneal stroma, but 
safety and efficacy data for of any combination of cells grown on BMSF membranes has yet to 
be reported. 
 
Artificial Corneas from Synthetically Produced Biologically Inspired Materials 
Although extracted ECM macromolecules have now been used for tissue engineering, the 
extracted materials are often difficult to purify and are subject to batch-to-batch variation. There 
is a small but present risk of disease transmission from extracted animal products. From a tissue 
engineering perspective, native ECM macromolecules are often large, complex macromolecules 
and difficult to manipulate, as they lack suitable functional groups for chemical modification. 
 
• Self-Assembling Peptides as Corneal Scaffolds 
The ECM is made up of a range of biological polymers, which have self assembled. Smaller 
units of these proteins, sugars and lipids have therefore been tested for their ability to function as 
more controllable mimics of the ECM [33]. Of these, the peptides have been most extensively 
examined as they can form a wide range of structures including nanofibres that mimic the ECM.  
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There are several ways to design self-assembling peptides (SAPs) that are being 
evaluated for regenerative medicine. Ionically complementary peptides, which were first 
described in 1993 by Zhang and co workers, comprise short peptide repeats, with hydrophilic 
and hydrophobic “faces” that stack to form long, entangled fibres [34]. Peptide amphiphiles, 
comprise hydrophilic peptide sequences that are attached to a hydrophobic tail. 
 Connon et al. [35] designed two synthetic peptide amphiphiles that contain the well-
known cell adhesion motif from fibronectin RGD. These SAPs were then assembled into film 
coatings that were able to enhance adhesion, proliferation, and alignment of human corneal 
stromal fibroblasts, while inducing the formation of 3D lamellar-like stromal tissue in the 
absence of serum. Uzunalli et al. [36] incorporated laminin motifs into peptide amphiphiles that 
were developed as injectable scaffolds, and tested them in rabbit models of wound healing. They 
reported an increase in keratocyte migration into the surgically induced wound, resulting in 
enhanced stromal regeneration. The use of self-assembled peptides is an exciting and promising 
new technology, and in the near future, corneal implants fabricated from SAPs will likely be 
appearing in the literature. 
 
• Recombinant Human Collagen-Based Corneal Implants 
In contrast to the short self-assembling peptides, the recombinant collagens that have been 
produced and are commercially available, reproduce full-length collagen fibrils with the same 
amino acid sequence as human collagen. By co-expression of prolyl hydroxylase genes with the 
collagen genes, recombinant collagens with a similar degree of stability as naturally occurring 
material can be produced. Like native type I and III structural collagens, the recombinantly 
produced counterparts also assemble into their characteristic triple helices.  
! "+!
 Type III recombinant human collagen (RHCIII) has now been fabricated into corneal 
implants and have tested in a small Phase I clinical study by one of us (MG) as possible 
substitutes for donor corneas. These 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS) cross-linked RHCIII constructs, which 
were designed as simple mimics of the corneal stromal ECM, were implanted into the corneas of 
10 patients (nine with keratoconus and 1 with a central scar) in Sweden by anterior lamellar 
keratoplasty [37]. These cell-free implants induced the patient’s own epithelial cells to grow over 
the implants, while stromal cells migrated into the implants, anchoring them stably into the eye. 
The in-growth and/or proliferation of stromal cells actively continued over the four-year 
observation period [38]. Corneal nerves also regenerated over the four years. The regenerated 
neo-corneas remained seamlessly and stably integrated in the operated eyes (Figure 2) without 
any immunosuppression beyond a short course of prophylactic steroids, in comparison to the 
longitudinally followed donor cornea patients who received 12 months of steroids. There was no 
rejection in implanted patients while one patient out of the 9 donor grafted individuals (11%) had 
a rejection episode in keeping with the current statistics of 10-15% rejection within the first year 
of grafting [39].  There was no recruitment of inflammatory dendritic cells into the region of the 
implant. In contrast, patients transplanted with donor corneas showed dendritic cell migration 
into their central cornea. One patient underwent regrafting even though he had a clear and stably 
integrated cornea, since contact lenses required for good visual acuity could not be fitted. 
Significantly, the excised corneal button displayed a normal corneal architecture when examined 
by histology (Figure 3). Observations using in vivo confocal microscopy revealed that donor 
human cornea grafted eyes had abnormally tortuous nerves and stromal cell death was found. 
Regenerated neo-corneas displayed similar nerve morphology of parallel bundles although the 
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numbers were significantly fewer than in normal healthy corneas. The implanted patients had a 
4-year average corrected visual acuity of 20/54 and gained more than 5 Snellen lines of vision on 
an eye chart. This visual acuity can be improved with the use of more robust materials for better 
shape retention or a different suture retention method that does not impede epithelial re-grow 
into the centre of the cornea. Despite these remaining issues, RHC implants can nevertheless 
achieve stable regeneration and therefore, represent a potentially safe alternative to donor organ 
transplantation. 
 
Conclusions 
Despite being considered as arguably one of the most successful types of solid organ transplants, 
the limited supply and health risks associated with donor corneas have driven the quest for 
alternative tissue substitutes. While earlier strategies focused on the use of synthetic materials, 
recent iterations of these technologies have exploited incorporation of natural tissue, especially 
with respect to enabling better bio-integration. Later designs, however, are now actively 
exploiting the potential of naturally occurring biomaterials such as collagens and silk fibroin as 
scaffolds for tissue reconstruction and/or delivery of cell-based therapies. Furthermore, recent 
progress in the design and production of synthetic self-assembling peptides, seems likely to pave 
the way for a new generation of corneal tissue substitutes which when used in conjunction with 
co-emergent technologies (e.g. induced pluripotent cells stems) might soon be tailored to meet 
the needs of individual patients. 
 
Key points:  
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• Artificial corneas based on naturally occurring biomaterials and structural/functional mimics 
have now been developed. 
• The design and development of a selection of these biological based or inspired implants are 
discussed. 
• Highlights include the use of silk based material as a potential scaffolds for corneal stem 
cell grafting, and the long-term clinical trial results showing stable regeneration of corneal 
tissue and nerves without immunosuppression after implantation with recombinant human 
collagen-based artificial corneas. 
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Figure Legends 
 
Figure 1. Schema of proposed strategy for fabricating an artificial corneal transplant using silk 
fibroin membranes in conjunction with cultured cells (modified from a similar figure illustrated 
by Bray et al [23], according to a strategy proposed by Harkin et al [24] and Lawrence et al 
[26]). Conceptually, the required number of transparent fibroin membranes with cultured stromal 
cell layers (ideally maintained as keratocytes) could be combined with upper and lower layers 
composed of cultured limbal epithelial cells and corneal endothelial cells respectively grown on 
fibroin membranes. All three types of cells display acceptable growth on fibroin [20-25] and the 
membranes themselves are well tolerated when implanted into the corneal stroma of rabbits [22]. 
In vivo studies of the proposed construct have yet to be reported. 
 
Figure 2. Slit lamp biomicroscopy images of the regenerated corneas of all 10 patients at 4 years 
after grafting with a cell-free implant made from EDC/NHS crosslinked recombinant human 
collagen. Reproduced from Fagerholm et al. Biomaterials $&K!#%#+Q#%#(D!#+"%![38],!
 
Figure 3. (A) Histological section through a regenerated neo-cornea that was obtained after 4 
years post-operation, when the patient was re-grafted, showing a normal corneal morphology.  
with stratified epithelium (ep), lamellarly arranged stroma (s) and endothelium (en) that was left 
intact during the implantation. Part of the recombinant human collagen implant (i) is still present, 
showing a slow but active remodeling process over time. (B) Higher magnification showing an 
area of the cornea where remodeling is more advanced and the implant (i) is seamlessly blending 
! "*!
into the stroma (s). ep, epithelium. Scale bars, 100 !m. Reproduced from Fagerholm et al. 
Biomaterials $&K!#%#+Q#%#(D!#+"%![38], 



